Pharmamarketeer
wet- en regelgeving

ViiV seeks EU marketing nod for cabotegravir in combo with rilpivirine as first monthly, injectable treatment for HIV

1 augustus 2019
Pharma Biz

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the submission of a marketing authorisation application (MAA) to the

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)